Cart (0)

FAM133B Inhibitors

FAM133B inhibitors form a theoretical class of chemical compounds designed to selectively impede the activity of the FAM133B protein, which may play a role in cellular processes. The inhibition mechanisms of these compounds are predicated on their ability to bind to specific domains of the FAM133B protein, thereby obstructing its function. By doing so, the inhibitors prevent FAM133B from interacting with its natural substrates or partners within the cell, which is critical for its normal function. The design of these inhibitors is often guided by the structural details of FAM133B, obtained through techniques like X-ray crystallography or NMR spectroscopy. Such detailed structural insights enable the identification of potential binding sites that are unique to the FAM133B protein and are essential for its activity. By targeting these unique sites, FAM133B inhibitors aim to reduce the protein's activity without affecting other proteins with similar domains, ensuring a high degree of specificity. The specificity of FAM133B inhibitors is further refined through iterative processes of medicinal chemistry, where small changes to the chemical structure can lead to significant improvements in binding affinity and selectivity. This fine-tuning process is essential because it minimizes off-target effects that could disrupt other cellular functions. FAM133B inhibitors might also work by stabilizing the protein in an inactive conformation, or by preventing post-translational modifications that are necessary for its activity. Some of these inhibitors could function allosterically, binding to a site on the protein that is distinct from the active site, yet inducing conformational changes that reduce the protein's activity. The ultimate goal of these inhibitors is to downregulate the activity of FAM133B in a controlled manner, providing a tool for elucidating the protein's role in various cellular pathways and potentially offering a starting point for the development of research tools.

Items 1 to 10 of 12 total

Display:

Product Name	CAS #	Catalog #	QUANTITY	Price	Citations	RATING
Rapamycin	53123-88-9	sc-3504 sc-3504A sc-3504B	1 mg 5 mg 25 mg	$63.00 $158.00 $326.00	233	(4)
Rapamycin is an mTOR inhibitor that directly affects the mTORC1 pathway. FAM133B, which may play a role in intracellular processes regulated by mTOR, would have decreased functional activity as mTORC1 signaling is critical for such intracellular processes.
LY 294002	154447-36-6	sc-201426 sc-201426A	5 mg 25 mg	$123.00 $400.00	148	(1)
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. By inhibiting PI3K, it reduces the downstream activation of AKT, which in turn can decrease mTOR signaling. Reduced mTOR activity is likely to indirectly decrease FAM133B functional activity, given mTOR's role.
Wortmannin	19545-26-7	sc-3505 sc-3505A sc-3505B	1 mg 5 mg 20 mg	$67.00 $223.00 $425.00	97	(3)
Wortmannin is another potent PI3K inhibitor, which similarly to LY294002, can hinder AKT activation and subsequent mTOR signaling, potentially leading to reduced FAM133B activity based on mTOR's regulatory influence on related intracellular pathways.
PD 98059	167869-21-8	sc-3532 sc-3532A	1 mg 5 mg	$40.00 $92.00	212	(2)
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. Since FAM133B may be involved in signaling pathways that are downstream of MAPK, its activity could be indirectly decreased by the inhibition of this pathway.
U-0126	109511-58-2	sc-222395 sc-222395A	1 mg 5 mg	$64.00 $246.00	136	(2)
U0126 is also a MEK inhibitor, similar to PD98059, and would inhibit the MAPK/ERK pathway. This inhibition may result in decreased functional activity of FAM133B if it is involved in any processes downstream of MAPK/ERK signaling.
SB 203580	152121-47-6	sc-3533 sc-3533A	1 mg 5 mg	$90.00 $349.00	284	(5)
SB203580 is an inhibitor of p38 MAPK, a different member of the MAPK family. If FAM133B's activity is associated with pathways involving p38 MAPK, then its inhibition could lead to a decrease in FAM133B functional activity.
SP600125	129-56-6	sc-200635 sc-200635A	10 mg 50 mg	$40.00 $150.00	257	(3)
SP600125 inhibits the JNK pathway, another MAPK signaling pathway. Inhibition of JNK could reduce the functional activity of FAM133B if it is related to any JNK-dependent cellular processes.
Triciribine	35943-35-2	sc-200661 sc-200661A	1 mg 5 mg	$104.00 $141.00	14	(1)
Triciribine is an AKT inhibitor. By preventing AKT phosphorylation, it can decrease mTOR signaling. Given the central role of mTOR in cell growth and survival, its inhibition could reduce the functional activity of FAM133B.
Torin 1	1222998-36-8	sc-396760	10 mg	$245.00	7	(1)
Torin 1 is a potent inhibitor of both mTORC1 and mTORC2 complexes. By inhibiting these, Torin 1 would decrease FAM133B activity if FAM133B is linked with mTOR-regulated processes.
Bafilomycin A1	88899-55-2	sc-201550 sc-201550A sc-201550B sc-201550C	100 µg 1 mg 5 mg 10 mg	$98.00 $255.00 $765.00 $1457.00	280	(6)
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase. By disrupting proton gradients, it inhibits autophagy, a process that could be regulated by mTOR signaling, potentially affecting FAM133B activity.

Santa Cruz Animal Health is a leading provider of animal health care products. ©2026 Santa Cruz Biotechnology Inc. All Rights Reserved.
Toll-Free: 1-800-457-3801 - Terms & Conditions | Privacy Policy | Legal
“Santa Cruz Animal Health”, “San Juan Ranch”, the San Juan Ranch logo, “UltraCruz”, “Supplement of Champions”, are registered trademarks of Santa Cruz Biotechnology, Inc. All other trademarks are the property of their respective owners.

FAM133B Inhibitors

Rapamycin

LY 294002

Wortmannin

PD 98059

U-0126

SB 203580

SP600125

Triciribine

Torin 1

Bafilomycin A1